HC Wainwright Issues Positive Outlook for MDGL Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities researchers at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Madrigal Pharmaceuticals in a report issued on Friday, July 31st. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will earn ($0.10) per share for the quarter, up from their prior estimate of ($1.05). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($7.47) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q4 2026 earnings at $0.85 EPS, FY2026 earnings at ($4.47) EPS, FY2027 earnings at $8.32 EPS, FY2028 earnings at $31.34 EPS, FY2029 earnings at $48.44 EPS and FY2030 earnings at $77.98 EPS.

A number of other analysts have also weighed in on the stock. Citigroup reiterated an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 17th. Barclays dropped their price objective on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a research note on Monday. Evercore set a $649.00 price target on shares of Madrigal Pharmaceuticals in a research report on Thursday, May 7th. Canaccord Genuity Group increased their target price on shares of Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Finally, Wells Fargo & Company started coverage on Madrigal Pharmaceuticals in a research report on Monday, July 27th. They set an “overweight” rating and a $685.00 price target on the stock. Fifteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $689.93.

Madrigal Pharmaceuticals Trading Up 3.1%

Shares of NASDAQ:MDGL opened at $482.00 on Tuesday. The business has a 50-day moving average price of $515.78 and a 200-day moving average price of $498.88. The stock has a market cap of $11.13 billion, a price-to-earnings ratio of -37.39 and a beta of -1.01. Madrigal Pharmaceuticals has a 52-week low of $299.17 and a 52-week high of $615.00. The company has a quick ratio of 2.94, a current ratio of 3.20 and a debt-to-equity ratio of 0.65.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The firm had revenue of $364.25 million for the quarter, compared to analyst estimates of $352.13 million. During the same period in the previous year, the company earned ($1.90) earnings per share. The business’s quarterly revenue was up 71.2% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Centaurus Financial Inc. raised its holdings in Madrigal Pharmaceuticals by 5.0% during the third quarter. Centaurus Financial Inc. now owns 709 shares of the biopharmaceutical company’s stock worth $325,000 after purchasing an additional 34 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Madrigal Pharmaceuticals by 34.6% during the 4th quarter. Farther Finance Advisors LLC now owns 140 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 36 shares in the last quarter. Accent Capital Management LLC increased its holdings in shares of Madrigal Pharmaceuticals by 64.9% in the 4th quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 37 shares in the last quarter. Swiss Life Asset Management Ltd lifted its position in shares of Madrigal Pharmaceuticals by 6.8% during the 4th quarter. Swiss Life Asset Management Ltd now owns 690 shares of the biopharmaceutical company’s stock valued at $402,000 after acquiring an additional 44 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of Madrigal Pharmaceuticals by 35.4% in the 2nd quarter. GAMMA Investing LLC now owns 172 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 45 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Insider Transactions at Madrigal Pharmaceuticals

In related news, Director Richard S. Levy sold 5,682 shares of Madrigal Pharmaceuticals stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $515.44, for a total value of $2,928,730.08. Following the sale, the director directly owned 22,015 shares in the company, valued at approximately $11,347,411.60. The trade was a 20.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $495.74, for a total value of $516,561.08. Following the sale, the insider owned 10,033 shares of the company’s stock, valued at approximately $4,973,759.42. This trade represents a 9.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,568 shares of company stock worth $3,880,711 over the last ninety days. 17.60% of the stock is currently owned by corporate insiders.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-? agonist in Phase 3 development for the treatment of NASH.